Evidence map›Paper›PMID 40922409›Full record

ArticleActa anaesthesiologica Scandinavica2025

Pro- and Anti-Inflammatory Responses and Clinical Outcomes in Critically Ill Patients With Endotheliopathy: A Cohort Study.

Caroline Humble, Martin Schønemann-Lund, Peter Bruun-Rasmussen, Morten H Bestle, Pär I Johansson, Lone M Poulsen, Ole Mathiesen

Abstract read
In one paragraph

Article in Acta anaesthesiologica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Caroline HumbleCentre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, Køge, Denmark.ORCID 0000-0001-7919-2946
Martin Schønemann-LundDepartment of Anaesthesiology and Intensive Care, Copenhagen University Hospital-North Zealand, Hillerød, Denmark.
Peter Bruun-RasmussenClinical Academic Group (CAG) Center for Endotheliomics, Department of Clinical Immunology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Morten H BestleDepartment of Anaesthesiology and Intensive Care, Copenhagen University Hospital-North Zealand, Hillerød, Denmark.ORCID 0000-0001-6585-2659
Pär I JohanssonClinical Academic Group (CAG) Center for Endotheliomics, Department of Clinical Immunology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0001-9778-5964
Lone M PoulsenCentre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, Køge, Denmark.ORCID 0000-0002-7030-3395
Ole MathiesenCentre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, Køge, Denmark.ORCID 0000-0003-4544-0619

Funding

A. P. Moller FoundationClinical Academic Group (CAG) Center for EndotheliomicsGreater Copenhagen Health Science PartnersIntensive Care Symposium HindsgavlKing Christian X FundRegion Zealand Health Science Research FundThe Danish Society of Anaesthesiology and Intensive Care Medicine (DASAIM)
6 · The paper itself

Abstract

backgroundMultiple organ dysfunction syndrome (MODS) in critical illness involves dysregulated immune and inflammatory responses, endotheliopathy, and coagulation activation. We investigated how three types of endotheliopathy biomarkers relate to pro- and anti-inflammatory responses and clinical outcomes in intensive care unit (ICU) patients.

methodsIn this secondary, explorative analysis of a prospective single-centre cohort (n = 459), we assessed associations between endotheliopathy biomarkers (syndecan-1, soluble thrombomodulin (sTM), platelet endothelial cell adhesion molecule-1 (PECAM-1)) and inflammatory biomarkers (pro-inflammatory: IFN-ϒ, IL-1β, IL-2, IL-6, IL-8, IL-12p70, TNF-α; anti-inflammatory: IL-4, IL-10, IL-13) at ICU admission using linear regression. Associations with 30-day clinical outcomes were analysed using linear and Cox regression. All models were adjusted for age, sex, septic shock, pre-ICU surgery and chronic disease.

resultsHigher levels of all three endotheliopathy biomarkers were associated with higher levels of inflammatory biomarkers. PECAM-1, however, showed no significant association with IFN-ϒ, IL-1β and IL-12p70. IL-4 was excluded from linear regression due to > 50% imputed values. Higher levels of all three endotheliopathy biomarkers were significantly associated with increased mean and maximum modified Sequential Organ Failure Assessment (mSOFA) scores over 30 days, as well as with renal, hepatic, and coagulation failure, and 30-day all-cause mortality. Only sTM was significantly associated with cardiovascular failure; none were significantly associated with respiratory failure. Higher levels of sTM were associated with the highest levels of inflammatory biomarkers, the largest increases in mean and maximum mSOFA scores, and the highest hazard ratios for organ failure and 30-day all-cause mortality, compared with syndecan-1 and PECAM-1.

conclusionIn this cohort of critically ill ICU patients, endotheliopathy was associated with (1) higher levels of pro- and anti-inflammatory biomarkers at ICU admission and (2) MODS, single organ failure, and 30-day all-cause mortality. Among the three endotheliopathy biomarkers, sTM demonstrated the most consistent and strongest associations with both inflammatory biomarkers and clinical outcomes. These findings are exploratory and should be interpreted as hypothesis-generating. EDITOR'S COMMENT: In this analysis of different biomarkers in a critically ill cohort, associations are demonstrated between markers related to endothelial stress, cytokines related to modulation of inflammation, and severity of illness scores.

Indexed as

Critical IllnessInflammationMultiple Organ FailureAgedBiomarkersCohort StudiesCytokinesFemaleHumansIntensive Care UnitsMaleMiddle AgedPlatelet Endothelial Cell Adhesion Molecule-1Prospective StudiesThrombomodulinBiomarkersCytokinesPlatelet Endothelial Cell Adhesion Molecule-1Thrombomodulin

Identifiers

PMID40922409
PMCPMC12417775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.